Loading clinical trials...

COMPLETEDPHASE3

Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease

A Multicenter, Randomized, Double-blind, 2 Parallel Group, Phase 3 Study of PENNEL Capsule in Chronic Liver Disease

NCT01393678•PharmaKing

Summary

The drug in this study is combined product of biphenyl dimethyl dicarboxylate (DDB) and garlic oil. This components showed synergistic enhancing effects in previous tests. In phase 2 test, 6 cap three times a day dosage (2cap T.I.D) is better than other dosage. Based on above, this study is phase 3 test to prove efficacy and safety of PENNEL.

Eligibility

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients diagnosed with chronic hepatitis by biopsy
•Patients over 20, under 65 years of age.
•Patients with abnormal transaminase value.

Exclusion Criteria

•Pregnant and lactating women.
•Patients who have any history of esophageal bleeding, hepatic encephalopathy, ascites.
•Diabetes, thyroid dysfunction, fatty liver, liver cancer patients.
•Toxic hepatitis, alcoholic hepatitis.
•Total bilirubin value more than 3.0 mg/dl.
•Albumin value less than 3.0 g/dl.
•Patients who participating in other study about drug.

Locations (1)

Hanyang University Hospital

Seoul, Seongdong-gu,, South Korea

Key Dates

Start Date

November 1, 1997

Primary Completion Date

March 1, 1998

Completion Date

May 1, 1998

Last Updated

July 13, 2011

Enrollment

220

ACTUAL participants

Conditions

Chronic Liver Disease

Interventions

NISSEL

DRUG

PENNEL

DRUG

Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry

NCT07480057

Chronic Liver Disease and ACLF

View study

RECRUITING

LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study

NCT06181409

Advanced Chronic Liver Disease

View study

RECRUITINGPHASE4

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

NCT06449339

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 13, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease

Inclusion Criteria

Exclusion Criteria

Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry

LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

Albumin Modifications as Early Biomarkers of Chronic Liver Diseases

Non-invasive Methods for Predicting Decompensation of Chronic Liver Disease

VIATORR Device Registry